BACKGROUND: A new ELISA for 65 kDa isoform of glutamic acid decarboxylase autoantibodies (GAD(65) Abs), which depends on GAD(65) Ab acting divalently and forming a bridge between immobilized GAD(65) and liquid-phase GAD(65)-biotin, is described. METHODS: Sera (25 microl) were incubated in GAD(65)-coated ELISA plate wells followed by washing and incubation with GAD(65)-biotin. After a further wash step, GAD(65)-biotin bound was quantitated by addition of streptavidin peroxidase followed by tetramethylbenzidine. Assay calibration was with WHO reference preparation 97/550. RESULTS: Using a cut-off for positivity of 5 units/ml, sera from 0.7% (2/300) healthy blood donors (HBDs), 100% (39/39) selected type 1 diabetes mellitus (DM) patients, 1.6% (1/62) type 2 diabetes mellitus patients and 3% (4/119) autoimmune disease controls were GAD(65) Ab positive in the ELISA. Levels of positivity in an immunoprecipitation assay (IPA) based on 125I-labelled GAD(65) (cut-off 25 units/ml) were 1%, 82%, 0% and 3%, respectively. ELISA inter-assay coefficients of variation (n=12) were 7.3%, 3.8%, 7.2% and 6.3% at 5.4, 40.8, 137 and 382 units/ml, respectively. CONCLUSIONS: The ELISA we have described has sensitivity and specificity at least as high as current radioactive assays. It has good precision and handling making it suitable for routine use.
BACKGROUND: A new ELISA for 65 kDa isoform of glutamic acid decarboxylase autoantibodies (GAD(65) Abs), which depends on GAD(65) Ab acting divalently and forming a bridge between immobilized GAD(65) and liquid-phase GAD(65)-biotin, is described. METHODS: Sera (25 microl) were incubated in GAD(65)-coated ELISA plate wells followed by washing and incubation with GAD(65)-biotin. After a further wash step, GAD(65)-biotin bound was quantitated by addition of streptavidin peroxidase followed by tetramethylbenzidine. Assay calibration was with WHO reference preparation 97/550. RESULTS: Using a cut-off for positivity of 5 units/ml, sera from 0.7% (2/300) healthy blood donors (HBDs), 100% (39/39) selected type 1 diabetes mellitus (DM) patients, 1.6% (1/62) type 2 diabetes mellituspatients and 3% (4/119) autoimmune disease controls were GAD(65) Ab positive in the ELISA. Levels of positivity in an immunoprecipitation assay (IPA) based on 125I-labelled GAD(65) (cut-off 25 units/ml) were 1%, 82%, 0% and 3%, respectively. ELISA inter-assay coefficients of variation (n=12) were 7.3%, 3.8%, 7.2% and 6.3% at 5.4, 40.8, 137 and 382 units/ml, respectively. CONCLUSIONS: The ELISA we have described has sensitivity and specificity at least as high as current radioactive assays. It has good precision and handling making it suitable for routine use.
Authors: L D K E Premawardhana; C N Wijeyaratne; S Chen; M Wijesuriya; U Illangasekera; H Brooking; M Amoroso; J Jeffreys; J Bolton; J H Lazarus; J Furmaniak; B Rees Smith Journal: J Endocrinol Invest Date: 2006-12 Impact factor: 4.256
Authors: Elizabeth M Bradshaw; Sally C Kent; Vinay Tripuraneni; Tihamer Orban; Hidde L Ploegh; David A Hafler; J Christopher Love Journal: Clin Immunol Date: 2008-10 Impact factor: 3.969
Authors: A Murray; C J Chapman; G Healey; L J Peek; G Parsons; D Baldwin; A Barnes; H F Sewell; H A Fritsche; J F R Robertson Journal: Ann Oncol Date: 2010-02-02 Impact factor: 32.976
Authors: C Wasserfall; E Montgomery; L Yu; A Michels; R Gianani; A Pugliese; C Nierras; J S Kaddis; D A Schatz; E Bonifacio; M A Atkinson Journal: Clin Exp Immunol Date: 2016-05-04 Impact factor: 4.330
Authors: Vito Lampasona; David L Pittman; Alistair J Williams; Peter Achenbach; Michael Schlosser; Beena Akolkar; William E Winter Journal: Clin Chem Date: 2019-08-13 Impact factor: 12.167
Authors: Alistair J K Williams; Vito Lampasona; Michael Schlosser; Patricia W Mueller; David L Pittman; William E Winter; Beena Akolkar; Rebecca Wyatt; Cristina Brigatti; Stephanie Krause; Peter Achenbach Journal: Diabetes Date: 2015-05-13 Impact factor: 9.461